



Free image

Docket No.: 14090-00004-US1
(PATENT)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of:
Ze-Yi Lim et al.

Application No.: 10/577,462

Confirmation No.:

Filed: April 27, 2006

Art Unit: N/A

For: ACYLUREA CONNECTED AND
SULFONYLUREA CONNECTED
HYDROXAMATES

Examiner: Not Yet Assigned

INFORMATION DISCLOSURE STATEMENT (IDS)

MS Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

Pursuant to 37 CFR 1.56, 1.97 and 1.98, the attention of the Patent and Trademark Office is hereby directed to the references listed on the attached PTO/SB/08. It is respectfully requested that the information be expressly considered during the prosecution of this application, and that the references be made of record therein and appear among the "References Cited" on any patent to issue therefrom.

This Information Disclosure Statement is filed within three months of the U.S. filing date (37 CFR 1.97(b)(1)).

A summary/abstract translation of the non-English language references is enclosed.

In accordance with 37 CFR 1.98(a)(2)(ii), Applicant has not submitted copies of U.S. patents and U.S. patent applications. Applicant submits herewith copies of foreign patents and non-patent literature in accordance with 37 CFR 1.98(a)(2).

In accordance with 37 CFR 1.97(g), the filing of this Information Disclosure Statement shall not be construed to mean that a search has been made or that no other material information as defined in 37 CFR 1.56(a) exists. In accordance with 37 CFR 1.97(h), the filing of this Information Disclosure Statement shall not be construed to be an admission that any patent, publication or other information referred to therein is "prior art" for this invention unless specifically designated as such.

It is submitted that the Information Disclosure Statement is in compliance with 37 CFR 1.98 and the Examiner is respectfully requested to consider the listed references.

The Director is hereby authorized to charge any deficiency in the fees filed, asserted to be filed or which should have been filed herewith (or with any paper hereafter filed in this application by this firm) to our Deposit Account No. 22-0185, under Order No. 14090-00004-US1. A duplicate copy of this paper is enclosed.

Dated: July 27, 2006

Respectfully submitted,

By 

Donald K. Drummond

Registration No.: 52,834
CONNOLLY BOVE LODGE & HUTZ LLP
1990 M Street, N.W., Suite 800
Washington, DC 20036
(202) 331-7111
(202) 293-6229 (Fax)
Attorney for Applicant



Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Project (0651-0031), no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/B/PTO			Complete if Known		
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)			Application Number	10/577,462	
			Filing Date	April 27, 2006	
			First Named Inventor	Ze-Yi Lim	
			Art Unit	N/A	
			Examiner Name	Not Yet Assigned	
Sheet	1	of	2	Attorney Docket Number	14090-00004-US1

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number Number-Kind Code ² (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	1	US-6,552,065 B2	04-22-2003	REMISZEWSKI et al.	

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No.	Foreign Patent Document	Publication Date	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Country Code ³ -Number ⁴ -Kind Code ⁵ (if known)	MM-DD-YYYY			
	2	WO 03/066579 A2	08-14-2003	AXYS PHARMACEUTICALS		
	3	WO 01/38322 A1	05-31-2001	METHYLGENE, INC.		
	4	EP 334720 B1	11-19-1992	SOCIETE NATIONALE DES POUDRES ET EXPLOSIFS		
	5	EP 334720 A1	09-27-1989	SOCIETE NATIONALE DES POUDRES ET EXPLOSIFS		
	6	JP 2004143053 A	05-20-2004	SENJU SEIYAKU KK		

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinda Codes of USPTO Patent Documents at www.uspto.gov or MPEP 801.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

NON PATENT LITERATURE DOCUMENTS					
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.			T ²
	7	WADE, P.A., "Transcriptional control at regulatory checkpoints by histone deacetylases: molecular connections between cancer and chromatin", Hum. Mol. Genet. Vol. 7, Pgs. 693-698, (2001)			
	8	DE RUIJTER, A.J.M. et al, "Histone deacetylases (HDACs): characterization of the classical HDAC family", Biochem. J., 370, Pgs. 737-749, (2003)			
	9	RICHON, V.M. et al, "Second generation hybrid polar compounds are potent inducers of transformed cell differentiation", Proc. Natl. Acad. Sci. USA, Vol. 93, Pgs. 5705-5708, (1996)			
	10	RICHON, V.M. et al, "A class of hybrid polar inducers of transformed cell differentiation inhibits histone deacetylases", Proc. Natl. Acad. Sci. USA, Vol. 95, Pgs. 3003-3007, (1998)			
	11	BUTLER, L.M. et al, "Suberoylanilide hydroxamic acid, an inhibitor of histone deacetylase, suppresses the growth of prostate cancer cells <i>in vitro</i> and <i>in vivo</i> ", Cancer Res. Vol. 60, Pgs. 5165-5170, (2000)			

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Examiner Signature	/Binta Robinson/	Date Considered	10/27/2008
--------------------	------------------	-----------------	------------

478177

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH: /BR/



Approved for use through 07/31/2008. OMB 0851-0031
U.S. Patent and Trademark Office, U.S. DEPARTMENT OF COMMERCE
Under the Patent Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/B/PTO		Complete if Known			
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)		Application Number	10/577,462		
		Filing Date	April 27, 2006		
		First Named Inventor	Ze-Yi Lim		
		Art Unit	N/A		
		Examiner Name	Not Yet Assigned		
Sheet	2	of	2	Attorney Docket Number	14090-00004-US1

12	YOSHIDA, M. et al, "Potent and Specific Inhibition of Mammalian Histone Deacetylase Both <i>in Vivo</i> and <i>in Vitro</i> by Trichostatin A", J. Biol. Chem., Vol. 265, Pgs. 17174-17179, (1990)	
13	KIJIMA, M. et al, Tapoxin, an Antitumor Cyclic Tetrapeptide, Is an Irreversible Inhibitor of Mammalian Histone Deacetylase", J. Biol. Chem., Vol. 268, No. 30, Pgs. 22429-22435, (1993)	
14	BOUCHAIN, G. et al, "Development of Potential Antitumor Agents. Synthesis and Biological Evaluation of a New Set of Sulfonamide Derivatives as Histone Deacetylase Inhibitors", J. Med. Chem., Vol. 46, Pgs. 820-830 (2003)	
15	STEFFAN, J.S. et al, "Histone deacetylase inhibitors arrest polyglutamine-dependent neurodegeneration in <i>Drosophila</i> ", Nature, Vol. 413, (6857), Pgs. 739-743, October 18, 2001	
16	SCHINDLER et al., "Dissociation between Interleukin-1 β mRNA and Protein Synthesis in Human Peripheral Blood Mononuclear Cells", J. Biol. Chem., Vol. 265, No. 18, Pgs. 10232-10237, (1990)	
17	J. Taunton et al, "A Mammalian Histone Deacetylase Related to the Yeast Transcriptional Regulator Rpd3p", Science 1996 Vol. 272, Pgs. 408-411	
18	CARBALLO et al, "Feedback Inhibition of Macrophage Tumor Necrosis Factor- α Production by Tristetraprolin", Science, Vol. 281, Pgs. 1001-1005, August 14, 1998	
19	DINARELLO, C.A. and MOLDAUER L.L. "Proinflammatory and anti-inflammatory cytokines in rheumatoid arthritis", A primer for clinicians, 3 rd Edition 2002, Amgen Inc., Pgs. 1-351	
20	Chauzov, V.A.; Baukov, Yu. I. <i>Zhurnal Obshchei Khimii</i> (1972), 42(8), 1868-9 (Abstract only)	
21	Kodama, H. et al. <i>Jpn. Tokkyo Koho</i> (1972) JP47009568 (Abstract only)	
22	BLAGOSKLONNY, M.V., " Prospective strategies to enforce selectively cell death in cancer cells", <i>Oncogene</i> (2004), Vol. 23, Pgs. 2967-2975	
23	KAUFMANN, S. H. et al., "Induction of Apoptosis by cancer chemotherapy", <i>Experimental Cell Research</i> , Vol. 256, Pgs. 42-49 (2000)	
24	TIECHER, PH.D., B. A. T., "In Vivo Tumor Response End Points", <i>Tumor Models in Cancer Research</i> , Pgs. 593-616, 2002	
25	SCOZZAFAVA, A. et al., "Protease inhibitors-part 5. Alkyl/arylsulfonyl- and arylsulfonylureido/aryluureido- glycinen hydroxamate inhibitors of <i>Clostridium histolyticum</i> collagenase", <i>European Journal of Medicinal Chemistry</i> (2000), Vol. 35, Pgs. 299-307	
26	SUPURAN, C.T. et al., "Protease inhibitors- part 7 Inhibition of <i>Clostridium histolyticum</i> collagenase with sulfonylated derivatives of L-valine hydroxamate", <i>European Journal of Pharmaceutical Sciences</i> (2000), Vol. 10, Pgs. 67-76	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609 Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

*Applicant's unique citation designation number (optional). *Applicant is to place a check mark here if English language Translation is attached.

Examiner Signature	/Binta Robinson/	Date Considered	10/27/2008
--------------------	------------------	-----------------	------------

478177

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /BR/